The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer
Open accessAbstract
The retinoblastoma tumor suppressor (RB) protein is functionally inactivated in the majority of human cancers and is aberrant in one-third of all breast cancers. RB regulates G(1)/S-phase cell-cycle progression and is a critical mediator of antiproliferative signaling. Here the specific impact of RB deficiency on E2F-regulated gene expression, tumorigenic proliferation, and the response to 2 distinct lines of therapy was investigated in breast cancer cells. RB knockdown resulted in RB/E2F target gene deregulation and accelerated tumorigenic proliferation, thereby demonstrating that even in the context of a complex tumor cell genome, RB status exerts significant control over proliferation. Furthermore, the RB deficiency compromised the short-term cell-cycle inhibition following cisplatin, ionizing radiation, and antiestrogen therapy. In the context of DNA-damaging agents, this bypass resulted in increased sensitivity to these agents in cell culture and xenograft models. In contrast, the bypass of antiestrogen signaling resulted in continued proliferation and xenograft tumor growth in the presence of tamoxifen. These effects of aberrations in RB function were recapitulated by ectopic E2F expression, indicating that control of downstream target genes was an important determinant of the observed responses. Specific analyses of an RB gene expression signature in 60 human patients indicated that deregulation of this pathway was associated with early recurrence following tamoxifen monotherapy. Thus, because the RB pathway is a critical determinant of tumorigenic proliferation and differential therapeutic response, it may represent a critical basis for directing therapy in the treatment of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
The E2F transcriptional network: old acquaintances with new faces
Dimova, D. K., & Dyson, N. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208612 · Cited by 715
Targeted disruption of the three Rb-related genes leads to loss of G 1 control and immortalization
Sage, J., Mulligan, G. J., Attardi, L. D., Miller, A., Chen, S., Williams, B., Theodorou, E., & Jacks, T. (2000) · Genes & Development · doi:10.1101/gad.843200 · Cited by 582
Direct coupling of the cell cycle and cell death machinery by E2F
Nahle, Z., Polakoff, J., Davuluri, R. V., McCurrach, M. E., Jacobson, M. D., Narita, M., Zhang, M. Q., Lazebnik, Y., Bar-Sagi, D., & Lowe, S. W. (2002) · Nature Cell Biology · doi:10.1038/ncb868 · Cited by 421
Self-citation
Cited by
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Molecular mechanisms underlying RB protein function
Dick, F. A., & Rubin, S. M. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3567 · Cited by 569
G‐Quadruplexes: Targets in Anticancer Drug Design
Ou, T., Lu, Y., Tan, J., Huang, Z., Wong, K., & Gu, L. (2008) · ChemMedChem · doi:10.1002/cmdc.200700300 · Cited by 482
RB1: a prototype tumor suppressor and an enigma
Dyson, N. J. (2016) · Genes & Development · doi:10.1101/gad.282145.116 · Cited by 435
Metadata
- Authors
- Bosco, E. E., Wang, Y., Xu, H., Zilfou, J. T., Knudsen, K. E., Aronow, B. J., Lowe, S. W., & Knudsen, E. S.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-01-02
- Volume
- 117
- Issue
- 1
- Pages
- 218-228
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2159058669
- Cited by
- 192
- References
- 4
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. https://app.cochat.ai/papers/10.1172/jci28803
- The paper
- Bosco, E. E., Wang, Y., Xu, H., Zilfou, J. T., Knudsen, K. E., Aronow, B. J., Lowe, S. W., & Knudsen, E. S. (2007). The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci28803
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.